Poor prognosis of this specific type of TCC. Preclincally profound efficacy of combining COX 2/1 inhibitors with EGFR inhibitors. Limited human data of efficacy of EGFR inhibitors in this subtype and at least some epidemiologic data implying efficacy of NSAIDs in reducing bladder cancers. Epidemiologic studies did not test for bladder cancer subtypes. This evidence concerns the gene EGFR and urinary bladder carcinoma.